Caught me right before I went to bed.
One of the bridges was confirmed as $50,000 in the previous 10-Q (it's subtly mentioned in one of the financial clauses like halfway down). As for the other, we won't know until two weeks or so when the 10-K drops.
They had a 13-G filing last month or so that showed a reduced holding by one of their institutional investors I believe, but if I'm not mistaken, they were also the ones OVIT was in litigation with. If so, it would make sense they're withdrawing.
As for the settlement terms, they agreed on (if memory serves me correct) three payments over the next two years. If they aren't adequately met, the fines are heavily increased. It's also stuffed behind a corner on the 10-Q.
As far as I'm aware regarding AdnaGen, the deal is still in effect, given they hit major marketing milestones. I believe they have like a ~$62 million maximum return if so, but this was initiated circa 2011, and I wasn't following the company then.
Weis having 5.3 million shares is all that's keeping me tied in at the moment. If I catch word he's trying to relieve his position, it'll be a major red flag for me. That said, MM's are getting involved from what I gathered from a poster on another forum (based off the large volume trades at neutral prices), so that could either mean great news, or foreboding.
As a closing statement of disclosure, three of the four times I got ahold of him to ask a question or two, he conveniently tells me: "I'm in a meeting/I'm driving/I'm eating refrigerator hosing. Call back tomorrow 10:30 central." Not that I believe he wasn't in a meeting necessarily, but he has a terrible shareholder communication history, and I believe it's reflected in said behavior. Man's a legend in the pharmacology industry. Time will tell.
